Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC).
Wierzbicki
R
R
Department of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Ezzat
A
A
Abdel-Warith
A
A
Ayoub
A
A
Kagevi
I
I
Fadda
M
M
Sieck
J
J
Abdulkareem
M
M
Amin
T
T
Yazigi
A
A
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D005047:Etoposide